6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
6m ago	Hovnanian Enterprises Reports Fiscal 2026 Second Quarter Results
6m ago	LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
6m ago	KKR Sells CIRCOR Aerospace to Parker Hannifin for $2.55 Billion
7m ago	Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
7m ago	Intuitive Announces Innovations to Advance Quintuple Aim

About

90.64USD+3.43 +3.93%

Closed • Updated at 13:22 GMT+00:00

Market Cap$6.21B

Volume496.7K

Beta1.14

RSI52.73

Gross Margin89.25%

Health TechnologyPharmaceuticals: Major

Rhythm Pharmaceuticals, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026

Community Chat

Ask AI